CNBC's Karen Gilchrist discusses Novo Nordisk's new CEO and the pharma giant's move to cut its full-year guidance on weaker ...

Wegovy, the blockbuster weight-loss drug, is now available in Singapore more than two years after it was approved by the ...

Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...

Novo Nordisk's launch of NovoCare is showing signs of boosting Wegovy's sales, and the E.U.-U.S. trade deal adds stability ...

Novo Nordisk shares dropped as much as 17% Tuesday after the obesity drugmaker cut its full-year sales and profit outlook for ...

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

Novo Nordisk's technical chart is displaying a largely bearish trend amid a profit warning tied to its blockbuster obesity ...

Novo Nordisk stock plunges 22% after slashing 2025 sales and profit outlooks, citing weak GLP-1 drugs' uptake and rising ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Cosmetic surgeons are reporting a growing number of patients with sagging skin and facial hollowing after losing weight with ...

Danish leader will face a challenging landscape among competitors ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...